The Cerebellum

, Volume 6, Issue 4, pp 308–314

N-acetylcysteine and neurodegenerative diseases: Basic and clinical pharmacology

Original Article

Abstract

Increasing lines of evidence suggest a key role of oxidative stress in neurodegenerative diseases. Alzheimer’s disease, Parkinson’s disease, myoclonus epilepsy of the Unverricht-Lundborg type, spinocerebellar degeneration, tardive dyskinesia and Down’s syndrome have been associated with several mitochondrial alterations Oxidative stress can decrease cellular bioenergetic capacity, which will then increase the generation of reactive oxygen species resulting in cellular damage and programmed cell death. First, this review examines the mechanisms of action of N-acetylcysteine (NAC), an antioxidant and a free radical-scavenging agent that increases intracellular GSH, at the cellular level. NAC can act as a precursor for glutathione synthesis as well as a stimulator of the cytosolic enzymes involved in glutathione regeneration. The chemical properties of NAC include redox interactions particularly with other members of the group XIV elements (selenium, etc.) and ebselen, a lipid-soluble seleno-organic compound. Second, NAC has been shown to protect against oxidative stress-induced neuronal death in cultured granule neurons. Recent findings on the protective effect of NAC against 4-hydroxynonenal (HNE)-induced toxicity in cerebellar granule neurons are summarized. Finally, the protective pharmacokinetics of NAC in humans and the possible usefulness of NAC for the treatment of neurodegenerative diseases are discussed with reference to basic and clinical studies.

Key words

N-acetylcysteine ebselen neuronal death 4-hydroxynonenal cerebellar granule neurons 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Vecchiarelli A, Dottorini M, Pietrella D, Cociani C, Eslami A, Todisco T, Bistoni F. Macrophage activation by N-acetylcysteine in COPD patients. Chest. 1994;105:806–11.PubMedCrossRefGoogle Scholar
  2. 2.
    Sheffner AL. The reduction in vitro in viscosity of mucoprotein solutions by a new mucolytic agent, N-acetyl-L-cysteine. Ann N Y Acad Sci. 1963;106:298–310.PubMedGoogle Scholar
  3. 3.
    Boman G, Bäcker U, Larsson S, Melander B, Wåhlander L. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: Report of a trial organized by the Swedish Society for Pulmonary Diseases. Eur J Respir Dis. 1983;64:405–15.PubMedGoogle Scholar
  4. 4.
    Prescott LF. Paracetamol overdosage. Pharmacological considerations and clinical management. Drugs. 1983;25:290–314.PubMedCrossRefGoogle Scholar
  5. 5.
    Suter PM, Domenighetti G, Schaller MD, Laverriére MC, Ritz R, Perret C. N-acetylcysteine enhances recovery from acute lung injury in man. A randomized, double-blind, placebo-controlled clinical study. Chest. 1994;105:190–4.PubMedCrossRefGoogle Scholar
  6. 6.
    Särnstrand B, Tunek A, Sjödin K, Hallberg A. Effects of N-acetylcysteine stereoisomers on oxygen-induced lung injury in rats. Chem Biol Interact. 1995;94:157–64.PubMedCrossRefGoogle Scholar
  7. 7.
    Knuckey NW, Palm D, Primiano M, Epstein MH, Johanson CE. N-acetylcysteine enhances hippocampal neuronal survival after transient forebrain ischemia in rats. Stroke. 1995;26:305–11.PubMedGoogle Scholar
  8. 8.
    Miquel J, Ferrándiz ML, De Juan E, Sevila, I, Martínez M. N-acetylcysteine protects against age-related decline of oxidative phosphorylation in liver mitochondria. Eur J Pharmacol. 1995;292:333–5.PubMedGoogle Scholar
  9. 9.
    Witschi A, Junker E, Schranz C, Speck RF, Lauterburg BH. Supplementation of N-acetylcysteine fails to increase glutathione in lymphocytes and plasma of patients with AIDS. AIDS Res Hum Retroviruses. 1995;11:141–3.PubMedGoogle Scholar
  10. 10.
    Simonian NA, Coyle JT. Oxidative stress in neurodegenerative diseases. Ann Rev Pharmacol Toxicol. 1996;36:83–106.CrossRefGoogle Scholar
  11. 11.
    Cotgreave IA, Sandy MS, Berggren M, Moldéus PW, Smith MT. N-acetylcysteine and glutathione-dependent protective effect of PZ51 (Ebselen) against diquat-induced cytotoxicity in isolated hepatocytes. Biochem Pharmacol. 1987;36:2899–904.PubMedCrossRefGoogle Scholar
  12. 12.
    Arakawa M, Ushimaru N, Osada N, Oda T, Ishige K, Ito Y. N-acetylcysteine selectively protects cerebellar granule cells from 4-hydroxynonenal-induced cell death. Neurosci Res. 2006;55:255–63.PubMedCrossRefGoogle Scholar
  13. 13.
    Mayer M, Noble M. N-acetyl-l-cysteine is a pluripotent protector against cell death and enhancer of trophic factor-mediated cell survival in vitro. Proc Natl Acad Sci USA. 1994;91:7496–500.PubMedCrossRefGoogle Scholar
  14. 14.
    Bannai S, Tateishi N. Role of membrane transport in metabolism and function of glutathione in mammals. J Membr Biol. 1986;89:1–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Ishige K, Tanaka M, Arakawa M, Saito H, Ito Y. Distinct nuclear factor-κB/Rel proteins have opposing modulatory effects in glutamate-induced cell death in HT22 cells. Neurochem Int. 2005;47:545–55.PubMedCrossRefGoogle Scholar
  16. 16.
    Sen CK. Nutritional biochemistry of cellular glutathione. J Nutr Biochem. 1997;8:660–72.CrossRefGoogle Scholar
  17. 17.
    Meister A. Glutathione metabolism. Meth Enzymol. 1995;251:3–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Richman PG, Meister A. Regulation of γ-glutamyl-cysteine synthetase by nonallosteric feedback inhibition by glutathione. J Biol Chem 1975;250:1422–6.PubMedGoogle Scholar
  19. 19.
    Townsend DM, Tew KD, Tapiero H. The importance of glutathione in human disease. Biomed Pharmacother. 2003;57:145–55.PubMedCrossRefGoogle Scholar
  20. 20.
    Bump EA, Brown JM. Role of glutathione in the radiation response of mammalian cells in vitro and in vivo Pharmacol Ther. 1990;47:117–36.PubMedCrossRefGoogle Scholar
  21. 21.
    Ferrari G, Yan CY, Greene LA. N-acetylcysteine (d- and l-stereoisomers) prevents apoptotic death of neuronal cells. J Neurosci. 1995;15:2857–66.PubMedGoogle Scholar
  22. 22.
    Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med. 1989;6:593–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Moldéus P, Cotgreave IA. N-acetylcysteine. Methods Enzymol. 1994;234:482–92.PubMedCrossRefGoogle Scholar
  24. 24.
    Biewenga GP, Bast A. Reaction of lipoic acid with ebselen and hypochlorous acid. Meth Enzymol. 1995;251:303–14.PubMedCrossRefGoogle Scholar
  25. 25.
    Sies H. Ebselen: A glutathione peroxidase mimic. Methods Enzymol. 1994;234:476–82.PubMedCrossRefGoogle Scholar
  26. 26.
    Masumoto H, Sies H. The reaction of ebselen with peroxynitrite. Chem Res Toxicol. 1996;9:262–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Glass RS, Farooqui R, Sabahi M, Ehler KW. Formation of thiocarbonyl compounds in the reaction of ebselen oxide with thiols. J Org Chem. 1989;54:1092–7.CrossRefGoogle Scholar
  28. 28.
    Kruman I, Bruce-Keller AJ, Bredesen D Waeg G, Mattson MI. Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis. J Neurosci. 1997;17:5089–100.PubMedGoogle Scholar
  29. 29.
    Awasthi YC, Sharma R, Cheng JZ, Yang Y, Sharma A, Singhal SS, Awasthi S. Role of 4-hydroxynonenal in stressmediated mediated apoptosis signaling. Mol Aspects Med. 2003;24:219–30.PubMedCrossRefGoogle Scholar
  30. 30.
    Blanc EM, Kelly JF, Mark RJ, Waeg G, Mattson MP. 4-Hydroxynonenal, an aldehydic product of lipid peroxidation, impairs signal transduction associated with muscarinic acetylcholine and metabotropic glutamate receptors: possible action on Gαq/11. J Neurochem. 1997;69:570–80.PubMedCrossRefGoogle Scholar
  31. 31.
    Keller JN, Mattson MP. Roles of lipid peroxidation in modulation of cellular signaling pathways, cell dysfunction, and death in the nervous system. Rev Neurosci. 1998;9:105–16.PubMedGoogle Scholar
  32. 32.
    Neely MD, Zimmerman L, Picklo MJ, Ou JJ, Morales CR, Montine KS, Amaranth V Montine TJ. Congeners of Nα-acetyl-l-cysteine but not aminoguanidine act as neuro-protectants from the lipid peroxidation product 4-hydroxy-2-nonenal. Free Radic Biol Med. 2000;29:1028–36.PubMedCrossRefGoogle Scholar
  33. 33.
    Picklo MJ, Amarnath V, McIntyre JO, Graham DG, Montine TJ. 4-Hydroxy-2(E)-nonenal inhibits CNS mitochondrial respiration at multiple sites. J Neurochem. 1999;72:1617–24.PubMedCrossRefGoogle Scholar
  34. 34.
    Akaishi T, Nakazawa K, Sato K, Ohno Y, Ito, Y. 4-Hydroxynonenal modulates the long-term potentiation induced by L-type Ca2+ channel activation in the rat dentate gyrus in vitro Neurosci Lett. 2004;370:155–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Akaishi T, Nakazawa K, Sato K, Saito H, Ohno Y, Ito Y. Modulation of voltage-gated Ca2+ current by 4-hydroxynonenal in dentate granule cells. Biol Pharm Bull. 2004;27:174–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Markesbery WR Lovell MA. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer’s disease. Neurobiol Aging. 1998;19:33–6.PubMedCrossRefGoogle Scholar
  37. 37.
    McGrath LT, McGleenon BM, Brennan S, McColl D, McILroy S Passmore AP. Increased oxidative stress in Alzheimer’s disease as assessed with 4-hydroxynonenal but not malondialdehyde. QJM. 2001;94:485–90.PubMedCrossRefGoogle Scholar
  38. 38.
    Yamashita T, Ando Y, Obayashi K, Terazaki H, Sakashita N, Uchida K, Ohama E, Ando M, Uchino M. Oxidative injury is present in Purkinje cells in patients with olivopontocerebellar atrophy. J Neurol Sci. 2000;175:107–10.PubMedCrossRefGoogle Scholar
  39. 39.
    Ito Y, Arakawa M, Ishige K, Fukuda H. Comparative study of survival signal withdrawal- and 4-hydroxynonenal-induced cell death in cerebellar granule cells. Neurosci Res. 1999;35:321–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Kosuge Y, Koen Y, Ishige K, Minami K, Urasawa H, Saito H, Ito Y. S-allyl-L-cysteine selectively protects cultured rat hippocampal neurons from amyloid β-protein-and tunica-mycin-induced neuronal death. Neuroscience. 2003;122: 885–95.PubMedCrossRefGoogle Scholar
  41. 41.
    Meyer MJ, Mosely DE, Amarnath V, Picklo MJ. Metabolism of 4-hydroxy-trans-2-nonenal by central nervous system mitochondria is dependent on age and NAD+ availability. Chem Res Toxicol. 2004;17:1272–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Murphy TC, Amarnath V, Picklo MJ. Mitochondrial oxidation of 4-hydroxy-2-nonenal in rat cerebral cortex. J Neurochem. 2003;84:1313–21.PubMedCrossRefGoogle Scholar
  43. 43.
    Laurent A, Perdu-Durand E, Alary J, Debrauwer L, Cravedi JP. Metabolism of 4-hydroxynonenal, a cytotoxic product of lipid peroxidation, in rat precision-cut liver slices. Toxicol Lett. 2000;114:203–14.PubMedCrossRefGoogle Scholar
  44. 44.
    Srivastava S, Chandra A, Wang LF, Seifert WE, DaGue BB, Ansari NH, Srivastava SK, Bhatnagar A. Metabolism of the lipid peroxidation product, 4-hydroxy-trans-2-nonenal, in isolated perfused rat heart. J Biol Chem. 1998;273: 10893–900.PubMedCrossRefGoogle Scholar
  45. 45.
    Raha S, Robinson BH. Mitochondria, oxygen free radicals, disease and ageing. Trends Biochem Sci. 2000;25:502–8.PubMedCrossRefGoogle Scholar
  46. 46.
    Xie C, Lovell MA, Markesbery WR. Glutathione transferase protects neuronal cultures against four hydroxynonenal toxicity. Free Radic Biol Med. 1998;25:979–88.PubMedCrossRefGoogle Scholar
  47. 47.
    Bhagwat SV, Vijayasarathy C, Raza H, Mullick J, Avadhani NG. Preferential effects of nicotine and 4-(N-methyl-N-nitrosamine)-1-(3-pyridyl)-1-butanone on mitochondrial glutathione S-transferase A4-4 induction and increased oxidative stress in the rat brain. Biochem Pharmacol. 1998;56:831–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Arakawa M, Ishimura A, Arai Y, Kawabe K, Suzuki S, Ishige K, Ito Y. Characterization of 4-hydroxynonenal-induced neuronal death in cerebellar granule neurons. Neurosci Res. in press.Google Scholar
  49. 49.
    Cotgreave IA, Moldéus P. Methodologies for the analysis of reduced and oxidized N-acetylcysteine in biological systems. Biopharm Drug Dispos. 1987;8:365–75.PubMedCrossRefGoogle Scholar
  50. 50.
    Holdiness MR Clinical pharmacokinetics of N-acetylcysteine. Clin Pharmacokinet 1991;20:123–34.PubMedCrossRefGoogle Scholar
  51. 51.
    Watson WA, McKinney PE. Activated charcoal and acetylcysteine absorption: Issues in interpreting pharmacokinetic data. DICP. 1991;25:1081–4.PubMedGoogle Scholar
  52. 52.
    Martinez M, Martínez N, Hernández AI, Ferrándiz ML. Hypothesis: Can N-acetylcysteine be beneficial in Parkinson’s disease? Life Sci. 1999;64:1253–7.PubMedCrossRefGoogle Scholar
  53. 53.
    Farr SA, Poon HF, Dogrukol-Ak D, Drake J, Banks WA, Eyerman E, Butterfield DA, Morley JE. The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J Neurochem. 2003;84:1173–83.PubMedCrossRefGoogle Scholar
  54. 54.
    Neuwelt EA, Pagel MA, Hasler BP, Deloughery TG, Muldoon LL. Therapeutic efficacy of aortic administration of N-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model. Cancer Res. 2001;61:7868–74.PubMedGoogle Scholar
  55. 55.
    Thomas Dickey D, Muldoon LL, Kraemer DF, Neuwelt EA. Protection against cisplatin-induced ototoxicity by N-acetylcysteine in a rat model. Hear Res. 2004;193:25–30.PubMedCrossRefGoogle Scholar
  56. 56.
    Edwards MJ, Hargreaves IP, Heales SJ, Jones SJ, Ramachandran V, Bhatia KP, Sisodiya S. N-acetylcysteine and Unverricht-Lundborg disease: Variable response and possible side effects. Neurology. 2002;59:1447–9.PubMedGoogle Scholar
  57. 57.
    Hurd RW, Wilder BJ, Helveston WR, Uthman BM. Treatment of four siblings with progressive myoclonus epilepsy of the Unverricht-Lundborg type with N-acetylcysteine. Neurology. 1996;47:1264–8.PubMedGoogle Scholar
  58. 58.
    Selwa LM. N-acetylcysteine therapy for Unverricht-Lundborg disease. Neurology. 1999;52:426–7.PubMedGoogle Scholar
  59. 59.
    Jesberger JA, Richardson JS. Oxygen free radicals and brain dysfunction. Int J Neurosci. 1991;57:1–17.PubMedCrossRefGoogle Scholar
  60. 60.
    Galili R, Mosberg, Gil-Ad I, Weizman A, Melamed E, Offen D. Haloperidol-induced neurotoxicity-possible implications for tardive dyskinesia. J Neural Transm. 2000;107:479–90.PubMedCrossRefGoogle Scholar
  61. 61.
    Sadan O, Bahat-Stromza M, Gilgun-Sherki Y, Atlas D, Melamed E, Offen D. A novel brain-targeted antioxidant (AD4) attenuates haloperidol-induced abnormal movement in rats: Implications for tardive dyskinesia. Clin Neuropharmacol. 2005;28:285–8.PubMedCrossRefGoogle Scholar
  62. 62.
    Busciglio J, Yankner BA. Apoptosis and increased generation of reactive oxygen species in Down’s syndrome neurons in vitro. Nature. 1995;378:776–9.PubMedCrossRefGoogle Scholar
  63. 63.
    Lehesjoki AE, Koskiniemi M. Clinical features and genetics of progressive myoclonus epilepsy of the Univerricht-Lundborg type. Ann Med. 1998;30:474–80.PubMedCrossRefGoogle Scholar
  64. 64.
    Lohr JB, Browning JA. Free radical involvement in neuropsychiatric illnesses. Psychopharmacol Bull. 1995;31:159–65.PubMedGoogle Scholar
  65. 65.
    Adams JD, Klaidman LK, Odunze IN, Shen HC, Miller CA. Alzheimer’s and Parkinson’s disease. Brain levels of glutathione, glutathione disulfide, and vitamin E. Mol Chem Neuropathol. 1991;14:213–26.PubMedCrossRefGoogle Scholar
  66. 66.
    Jenner P. Oxidative damage in neurodegenerative disease. Lancet. 1994;344:796–8.PubMedCrossRefGoogle Scholar
  67. 67.
    Tchantchou F, Graves M, Rogers E, Ortiz D, Shea TB N-acetyl cysteine alleviates oxidative damage to central nervous system of ApoE-deficient mice following folate and vitamin E-deficiency. J Alzheimers Dis. 2005;7:135–8 discussion 173.PubMedGoogle Scholar
  68. 68.
    Tucker S, Ahl M, Bush A Westaway D, Huang X, Rogers JT. Pilot study of the reducing effect on amyloidosis in vivo by three FDA pre-approved drugs via the Alzheimer’s APP 5′ untranslated region. Curr Alzheimer Res. 2005;2:249–54.PubMedCrossRefGoogle Scholar
  69. 69.
    Pappert EJ, Tangney CC, Goetz CG, Ling ZD, Lipton JW, Stebbins GT, Carvey PM. Alpha-tocopherol in the ventricular cerebrospinal fluid of Parkinson’s disease patients: Dose-response study and correlations with plasma levels. Neurology. 1996;47:1037–42.PubMedGoogle Scholar
  70. 70.
    The Parkinson Study Group Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med. 1993;328:176–83.CrossRefGoogle Scholar
  71. 71.
    Reilly DK, Hershey L, Rivera-Calimlim L, Shoulson I. On-off effects in Parkinson’s disease: A controlled investigation of ascorbic acid therapy. Adv Neurol. 1983;37:51–60.PubMedGoogle Scholar
  72. 72.
    Park SW, Kim SH, Park KH, Kim SD, Kim JY, Baek SY, Chung BS, Kang CD. Preventive effect of antioxidants in MPTP-induced mouse model of Parkinson’s disease. Neurosci Lett. 2004;363:243–6.PubMedCrossRefGoogle Scholar
  73. 73.
    Behar TN, Colton CA. Redox regulation of neuronal migration in a Down Syndrome model. Free Radic Biol Med. 2003;35:566–75.PubMedCrossRefGoogle Scholar

Copyright information

© Taylor & Francis 2007

Authors and Affiliations

  1. 1.Research Unit of Pharmacology, Department of Clinical Pharmacy, College of PharmacyNihon UniversityFunabashi-shi, ChibaJapan

Personalised recommendations